Impact of Golimumab, An Anti-Tnfα Monoclonal Antibody, On Health Related Quality of Life (Hrqol) And Work Productivity In Patients With Active Psoriatic Arthritis- 24-Week Results of The Phase Iii Go Vibrant Trial
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.788
https://www.valueinhealthjournal.com/article/S1098-3015(17)31122-1/fulltext
Title :
Impact of Golimumab, An Anti-Tnfα Monoclonal Antibody, On Health Related Quality of Life (Hrqol) And Work Productivity In Patients With Active Psoriatic Arthritis- 24-Week Results of The Phase Iii Go Vibrant Trial
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31122-1&doi=10.1016/j.jval.2017.08.788
First page :
A538
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
755